Affinity Asset Advisors LLC Invests $9.86 Million in Tyra Biosciences, Inc. $TYRA

Affinity Asset Advisors LLC acquired a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the first quarter, HoldingsChannel.com reports. The fund acquired 257,512 shares of the company’s stock, valued at approximately $9,863,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares during the period. AQR Capital Management LLC lifted its holdings in Tyra Biosciences by 2.0% in the fourth quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock valued at $753,000 after buying an additional 562 shares during the period. MetLife Investment Management LLC lifted its holdings in Tyra Biosciences by 5.0% in the fourth quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock valued at $404,000 after buying an additional 725 shares during the period. Virtus Investment Advisers LLC boosted its position in Tyra Biosciences by 6.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock valued at $309,000 after acquiring an additional 741 shares during the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in Tyra Biosciences during the 1st quarter worth about $30,000. 84.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. Wolfe Research started coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Guggenheim assumed coverage on Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price target on the stock. Bank of America lifted their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, Canaccord Genuity Group initiated coverage on shares of Tyra Biosciences in a report on Monday, April 6th. They set a “buy” rating and a $50.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

Tyra Biosciences Stock Down 0.6%

TYRA opened at $30.63 on Friday. Tyra Biosciences, Inc. has a twelve month low of $9.96 and a twelve month high of $40.65. The company’s 50-day moving average price is $30.68 and its two-hundred day moving average price is $32.56. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -14.05 and a beta of 0.76.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). As a group, sell-side analysts anticipate that Tyra Biosciences, Inc. will post -2.68 earnings per share for the current year.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.